Back to School: How biopharma can reboot drug development. Access exclusive analysis here
In a double-blind, U.K. Phase IIa trial in 50 patients, ADX10059 missed the primary endpoint
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury